Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Crucell, Novartis Sign Licensing Deal | Contract Pharma

What are you searching for?

Sign in
Breaking News

Crucell, Novartis Sign Licensing Deal

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Crucell N.V. and Novartis Vaccines and Diagnostics, Inc. have extended a non-exclusive research license agreement for PER.C6. The agreement allows Novartis to use Crucell’s cell technology in manufacturing alphavirus vectors for its vaccine research programs. Financial details were not disclosed.

The PER.C6 technology is a cell line for the development and large-scale manufacture of biopharma products including vaccines.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters